AbbVie Aktie News

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.

Added 304,281 shares in AbbVie; estimated transaction value of $61.96 million Trade value was 0.23% of the fund's reportable U.S. equity assets under management Post-trade stake: 2,324,286 shares valued at $538.17 million as of September 30, 2025 The position now accounts for 2.01% of 13F assets, placing it outside the fund's top five holdings

Explore the exciting world of AbbVie (ABBV 1.17%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!

Each winner will be awarded a $20,000 grant to fuel their businesses. Since the program's inception, BOTOX® Cosmetic has awarded more than $1 million in grants to The Confidence Project entrepreneurs.

AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company's previous bestseller Humira, meeting the main goal of a head-to-head trial.

Upadacitinib demonstrated superiority versus adalimumab for  primary endpoint of achieving low disease activity (DAS28-CRP≤3.2) and ranked secondary endpoint of remission (DAS28-CRP

AbbVie earns a Strong Buy rating in my book, driven by Rinvoq's label expansions and robust immunology pipeline growth. ABBV achieved FDA approval for Rinvoq in giant cell arteritis and reported strong phase 3 results for severe alopecia areata, supporting long-term revenue growth. The acquisition of Capstan Therapeutics brings CPTX2309, a first-in-class tLNP CAR-T candidate, potentially transf...

Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). NORTH CHICAGO, Ill.